Evidence map›Paper›PMID 12801956›Full record

ArticleGut2003

Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC).

S Resta-Lenert, K E Barrett

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Gut, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 238 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed, 5 pooled it
17.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02544685 phase2unknown statusnot on this mapstarted 2010, after this paper: background citation

Prevention of Febrile Neutropenia in Pediatric Cancer Patients by Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subspecies. Lactis BB-12 in Combination With Inulin and Oligofructose

TypeinterventionalSponsorS&D Pharma SK s.r.o.Ran2010 to 2019Enrolled120ConditionsFebrile Neutropenia, Neutropenia, Infection in an Immunocompromised Host, CancerArmsProbio-Fix Inum, Beneo Synergy 1, Placebo
NCT02819960 phase3completednot on this mapstarted 2016, after this paper: background citation

Prevention of Irinotecan Induced Diarrhea by Probiotics: A Phase III Study

TypeinterventionalSponsorS&D Pharma SK s.r.o.Ran2016 to 2022Enrolled233ConditionsDiarrhea, CancerArmsProbio-Tec® BG-VCap-6.5, Placebo
3 · Its place in the literature

Who cites it

238 citing papers in PubMed, 5 syntheses or guidelines pooled it, 638 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2010
    Trial
  11. Article
  12. Article
  13. Article
  14. Comparative Immunomodulatory Profiles ofJournal of microbiology and biotechnology · 2026
    Article
  15. Article
  16. Frontiers in cellular and infection microbiology · 2026
    Article
  17. International journal of molecular sciences · 2025
    Article
  18. Article
  19. Article
  20. Article

178 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

S Resta-LenertDepartment of Medicine, School of Medicine, University of California-San Diego, UCSD Medical Center 8414, 200 West Arbor Drive, San Diego, CA 92103, USA. srestalenert@ucsd.edu
K E Barrett
University of California, San Diego · USUniversity of California San Diego Medical Center · US

Funding

TL MOLECULES AND GAMMA-DELTA T CELLSP01DK035108 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KAGNOFF, MARTIN FREDERICK · 1986 to 2013
$19.2M
NIDDK NIH HHS DK 35108NIDDK NIH HHS P01 DK035108
6 · The paper itself

Abstract

backgroundThe colonic epithelium maintains a life long reciprocally beneficial interaction with the colonic microbiota. Disruption is associated with mucosal injury.

aimsWe hypothesised that probiotics may limit epithelial damage induced by enteroinvasive pathogens, and promote restitution.

methodsHuman intestinal epithelial cell lines (HT29/cl.19A and Caco-2) were exposed to enteroinvasive Escherichia coli (EIEC 029:NM), and/or probiotics (Streptococcus thermophilus (ST), ATCC19258, and Lactobacillus acidophilus (LA), ATCC4356). Infected cells and controls were assessed for transepithelial resistance, chloride secretory responses, alterations in cytoskeletal and tight junctional proteins, and responses to epidermal growth factor (EGF) stimulation.

resultsExposure of cell monolayers to live ST/LA, but not to heat inactivated ST/LA, significantly limited adhesion, invasion, and physiological dysfunction induced by EIEC. Antibiotic killed ST/LA reduced adhesion somewhat but were less effective in limiting the consequences of EIEC invasion of cell monolayers. Furthermore, live ST/LA alone increased transepithelial resistance, contrasting markedly with the fall in resistance evoked by EIEC infection, which could also be blocked by live ST/LA. The effect of ST/LA on resistance was accompanied by maintenance (actin, ZO-1) or enhancement (actinin, occludin) of cytoskeletal and tight junctional protein phosphorylation. ST/LA had no effect on chloride secretion by themselves but reversed the increase in basal secretion evoked by EIEC. EIEC also reduced the ability of EGF to activate its receptor, which was reversed by ST/LA.

conclusionsLive ST/LA interact with intestinal epithelial cells to protect them from the deleterious effect of EIEC via mechanisms that include, but are not limited to, interference with pathogen adhesion and invasion. Probiotics likely also enhance the barrier function of naïve epithelial cells not exposed to any pathogen.

Indexed as

Cell AdhesionCell LineCell Membrane PermeabilityChloridesColonic DiseasesColony Count, MicrobialCytoskeletonDiarrheaEpithelial CellsErbB ReceptorsEscherichia coli InfectionsHumansImmunoblottingInflammatory Bowel DiseasesLactobacillus acidophilusMembrane ProteinsChloridesErbB ReceptorsMembrane Proteins

Identifiers

PMID12801956
PMCPMC1773702
OpenAlexW2097697877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.